title: Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
authors: Minh P
authors: MP
authors: Lê
authors: Anne
authors: A
authors: Gervais
authors: Christine
authors: C
authors: Le Beller
authors: Kivan
authors: K
authors: Long
authors: Lucile
authors: L
authors: Larrouy
authors: Emmanuelle
authors: E
authors: Papy
authors: Hervé
authors: H
authors: Mal
authors: Diane
authors: D
authors: Descamps
authors: Gilles
authors: G
authors: Peytavin
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D000077300:Bosentan; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced*; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced*; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D013449:Sulfonamides; C486464:telaprevir; D000077300:Bosentan